<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03857711</url>
  </required_header>
  <id_info>
    <org_study_id>q9ics7t8</org_study_id>
    <nct_id>NCT03857711</nct_id>
  </id_info>
  <brief_title>Randomized Clinical Trial PULVAB (Prophylactic Pulmonary Veins Ablation)</brief_title>
  <acronym>PULVAB</acronym>
  <official_title>Multicenter Randomized Clinical Trial PULVAB (Prophylactic Pulmonary Veins Ablation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Research Center of Surgery, Russia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Federal Centre of High Medical Technologies of the RF Ministry of Public Health, Kaliningrad, Russia.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Research Center of Surgery, Russia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare prophylactic strategies of atrial fibrillation in patients with CAD and without
      AF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective, multicenter, randomized trial, intended to compare three prophylactic strategies
      of atrial fibrillation in patients with coronary artery disease and without history of atrial
      fibrillation.

      The study includes 4 groups of patients:

      Group I (conventional CABG)

      Group II (CABG + pulmonary veins isolation). Concomitant CABG and epicardial bipolar
      radiofrequency pulmonary veins isolation.

      Group III (CABG+ pulmonary veins isolation + amiodarone). Concomitant CABG and epicardial
      bipolar radiofrequency pulmonary veins ablation with administration of amiodarone in
      postoperative periode.

      Group IV (CABG+ amiodarone). Conventional CABG with administration of amiodarone in
      postoperative periode.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 1, 2016</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Actual">December 1, 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of atrial fibrillation after CABG</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Major cardiovascular and cerebral events (MACCE), including death, nonfatal myocardial infarction, repeated revascularization using PCI or CABG, transitory ischemic attack (TIA) or stroke.</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sinus rhythm at the time of discharge of the patient from the hospital</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of implantation of the pacemaker</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of intraoperative bleeding</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of CBP</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time clamping of the aorta</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of stay in the intensive care unit</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of the hospitalization</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Arrhythmias, Cardiac</condition>
  <condition>Cardiovascular Diseases</condition>
  <condition>Postoperative Atrial Fibrillation</condition>
  <condition>Myocardial Ischemia</condition>
  <arm_group>
    <arm_group_label>Conventional CABG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary artery bypass grafting (CABG) treatment (CABG group,n=70)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG+ PVI</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CABG + prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation (CABG +PVI group, n=70)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG+ PVI+amiodarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CABG+ prophylactic epicardial bipolar radiofreaquency pulmonary veins isolation + amiodarone (CABG +PVI+ class III antiarrhythmic drug- amiodarone, group, n=70)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG+amiodarone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>CABG+class III antiarrhythmic drug- amiodarone, group, n=70</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional CABG</intervention_name>
    <description>Coronary artery bypass grafting</description>
    <arm_group_label>Conventional CABG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG+ PVI</intervention_name>
    <description>CABG+ prophylactic epicardial bipolar radiofrequency isolation of the pulmonary veins</description>
    <arm_group_label>CABG+ PVI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG+ PVI+amiodarone</intervention_name>
    <description>CABG+PVI+amiodarone (CABG+RFA + class III antiarrhythmic drug- amiodarone)</description>
    <arm_group_label>CABG+ PVI+amiodarone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG+amiodarone</intervention_name>
    <arm_group_label>CABG+amiodarone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients must have signed an informed consent.

          -  patients had indications for two or more coronary arteries to be bypassed

          -  no history of AF

        Exclusion Criteria:

          -  acute coronary syndrome

          -  previous CABG.

          -  a significant decrease in the contractile function of the heart (EF &lt;40%)

          -  significant heart valve disease requiring surgical repair

          -  long-standing persistent, persistent, or paroxysmal forms of atrial fibrillation

          -  respiratory failure

          -  left ventricular aneurysm requiring surgical correction

          -  chronic renal failure (≤60 mL/min/1⋅73 m2)

          -  chronic diseases that make a significant contribution to the prognosis of life (e.g.
             oncology)

          -  participation in other clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amiran Sh. Revishvili</last_name>
    <role>Study Chair</role>
    <affiliation>A.V. Vishnevsky National Medical Research Center of Surgery. Moscow. Russian Federation.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amiran Sh. Revishvili</last_name>
    <phone>+7 (499) 236-72-90</phone>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vadim A. Popov</last_name>
    <phone>+7 9166706609</phone>
    <email>drpopov@mail.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Federal Centre of High Medical Technologies of the RF Ministry of Public Health, Kaliningrad, Russia.</name>
      <address>
        <city>Kaliningrad</city>
        <zip>236035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuri A Schneider</last_name>
    </contact>
    <investigator>
      <last_name>Yuri A Schneider</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.V. Vishnevsky National Medical Research Center of Surgery.</name>
      <address>
        <city>Moscow</city>
        <zip>117997</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amiran Sh. Revishvili</last_name>
      <phone>+7 (499) 236-72-90</phone>
    </contact>
    <investigator>
      <last_name>Vadim A. Popov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 22, 2019</study_first_submitted>
  <study_first_submitted_qc>February 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2019</study_first_posted>
  <last_update_submitted>February 4, 2020</last_update_submitted>
  <last_update_submitted_qc>February 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Research Center of Surgery, Russia</investigator_affiliation>
    <investigator_full_name>Stepanova Yulia Aleksandrovna</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Bipolar radiofrequency ablation</keyword>
  <keyword>Atrial Fibrillation New Onset</keyword>
  <keyword>CABG</keyword>
  <keyword>Coronary artery disease</keyword>
  <keyword>Postoperative atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amiodarone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

